Form 4: ESSA Pharma Director Marella Thorell Acquires 50,000 Options
SEC Form 4 Filing
Director Marella Thorell reports acquisition of 50,000 options in ESSA Pharma Inc.
Summary
- On March 25, 2024, Marella Thorell, a director of ESSA Pharma Inc., acquired 50,000 options.
- The options have an exercise price of $9.04.
- The options are exercisable from March 25, 2025, and expire on March 25, 2034.
- Following the transaction, Thorell directly owns 50,000 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral event. It simply reflects a director acquiring options, which is a common practice.
Industry Context
This is a standard Form 4 filing, indicating a change in beneficial ownership by a company insider. It's common for directors and officers to receive stock options as part of their compensation.
Stakeholder Impact
- The acquisition of options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 03/25/2024 | Date of earliest transaction: Acquisition of 50,000 options. |
| 03/25/2025 | Options become exercisable. |
| 03/25/2034 | Options expiration date. |
| 03/28/2024 | Date of signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.